Our mission is to enhance target discovery for Alzheimer’s disease.
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s disease.
This multisector partnership, managed by the Foundation for the NIH, will focus on providing a data-driven approach for identification and validation of biomarkers that will lead to increased clinical trial success.
AMP AD 2.0 builds on the success of AMP AD 1.0 and joins a portfolio of AMP programs that use cutting-edge scientific approaches to bring new medicines and support to patients by enhancing validation of novel, clinically relevant therapeutic targets and biomarkers.
A Growing Crisis
Alzheimer’s disease is a type of dementia that affects the brain, particularly areas related to memory, thinking, and behavior. It is a progressive condition, which means that symptoms worsen over time, and is projected to affect approximately 14 million people by the year 2060. Alzheimer’s disease is caused by the buildup of abnormal protein clumps and tangles in the brain, which damage and eventually kill brain cells. In the early stages of Alzheimer’s, a person may experience forgetfulness and difficulty with planning or problem-solving. This leads to a progressive loss of cognitive functions, and symptoms worsen and interfere with daily life and activities.
Need for New Therapies
Despite substantial investment in Alzheimer’s disease research, the treatment options available today only temporarily improve symptoms without stopping the underlying cognitive decline and death of brain cells. Given the extremely high failure rate for investigative Alzheimer’s treatments – nearly 100 percent – this field needs innovations to enable an understanding of the complex biology and heterogeneity of the disease process.
Private Sector Partners
Public Sector Partners
Deepening our understanding of Alzheimer’s disease at the molecular level and across diverse populations is an enormous undertaking—but critical to achieving the therapeutic breakthroughs we need. The AMP AD collaboration is leading the way in this effort and in ensuring the data, methods, and results are open and accessible.
At Eisai, we believe collaboration is crucial in the fight against Alzheimer’s disease and we are proud to partner with leading organizations from the public, nonprofit and private sectors as part of Accelerating Medicines Partnership 2.0 for Alzheimer’s disease.
AMP AD Knowledge Portal
Discover and download Alzheimer’s disease data, analyses, and tools from AMP AD.Learn More
AMP AD Agora Platform
Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer’s disease.Learn More